Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.48 |
| ▸ | WNT3A | P56704 | 7/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | BRD1 | O95696 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674134 | 0.89 | CA2 (0.59) | KEAP1NFE2L2CTNNB1WNT3ACA12 | |
| SCHEMBL968326 | 0.80 | PKM (0.57) | KEAP1NFE2L2CA12CA1CA2 | |
| SCHEMBL12365525 | 0.78 | KDM4E (0.67) | KEAP1NFE2L2CTNNB1WNT3APKM | |
| SCHEMBL18587031 | 0.77 | CA2 (0.59) | KEAP1NFE2L2CA12CA1CA2 | |
| SCHEMBL6307961 | 0.77 | KEAP1 (0.51) | KEAP1NFE2L2CTNNB1WNT3ACA12 | |
| SCHEMBL2316022 | 0.77 | KEAP1 (0.45) | KEAP1NFE2L2CTNNB1WNT3APKM | |
| Glycine SCHEMBL27902182 | 0.76 | CTNNB1 (0.52) | KEAP1NFE2L2CTNNB1WNT3ATDP1 | |
| SCHEMBL12596097 | 0.74 | TRIM24 (0.51) | KEAP1NFE2L2CTNNB1WNT3APKM | |
| SCHEMBL5747283 | 0.74 | PKM (0.49) | KEAP1NFE2L2CTNNB1WNT3ACA12 | |
| SCHEMBL31396966 | 0.72 | TSHR (0.66) | KEAP1NFE2L2CTNNB1WNT3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536704-B1 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8404741-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8354548-B2 | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102858753-A | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO | 2013-01-02 | — | — | CN | disclosed |
| CN-102858760-A | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase | BRISTOL MYERS SQUIBB CO | 2013-01-02 | — | — | CN | disclosed |
| EP-2536704-A1 | GLYCINE CHROMAN-6-SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | Bristol-Myers Squibb Company (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2536704-A1 | GLYCINE CHROMAN-6-SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | Bristol-Myers Squibb Company (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
| WO-2011103156-A1 | GLYCINE CHROMAN-6-SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103156-A1 | GLYCINE CHROMAN-6-SULFONAMIDES FOR USE AS INHIBITORS OF DIACYLGLYCEROL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110207772-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207749-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | DAGLB, DAGLA, MGLL | KEAP1 2888/4885NFE2L2 4799/4885CTNNB1 2916/4885 |
| US-20110207772-A1 | Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase | DAGLB, DAGLA, MGLL | KEAP1 2888/4885NFE2L2 4799/4885CTNNB1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.